drugset / Trial / NCT00377715

Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease

NCT00377715

Phase 2 Completed 183 enrolled Medivation, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and potential benefit of Dimebon as compared to placebo in patients with mild to moderate Alzheimer's Disease.

Timeline

Start
2005-09
Primary completion
2006-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Latrepirdine Small molecule 20 mg Oral

Indications